NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free KLDO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume100 shsAverage Volume3,408 shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends Get Kaleido Biosciences alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Kaleido Biosciences Stock (NASDAQ:KLDO)Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. KLDO Stock News HeadlinesApril 5, 2024 | fool.comKaleido Biosciences (OTC: KLDO)April 4, 2024 | finance.yahoo.comKaleido and Emma Join Forces to Help Families Secure Their Financial Future: An Innovative PartnershipApril 2, 2024 | finance.yahoo.comChange in management Kaleido IDEO+ individual RESP portfoliosDecember 20, 2023 | finance.yahoo.comMobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido IntelligenceDecember 20, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: Mobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido IntelligenceDecember 14, 2023 | finance.yahoo.comKaleido Intelligence to Launch Huge Enterprise Connectivity Survey in 2024November 22, 2023 | finanznachrichten.deViCentra: Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetesNovember 14, 2023 | finance.yahoo.comEseye, G+D, Thales and Vodafone Recognised as Champion Connectivity Vendors by Kaleido IntelligenceNovember 7, 2023 | bizjournals.comLocal tech startup brings augmented reality to art marketNovember 5, 2023 | morningstar.comKaleido Biosciences Inc KLDOOctober 24, 2023 | finance.yahoo.comNokia and NTT DATA Recognised as Champion Private Network Vendors by Kaleido IntelligenceOctober 16, 2023 | tmcnet.comSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Third Straight YearOctober 12, 2023 | finanznachrichten.deBroadForward earns top rating from Kaleido for BroadForward Signaling Security and Firewall productsOctober 10, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: BICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido IntelligenceOctober 10, 2023 | finance.yahoo.comBICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido IntelligenceSeptember 13, 2023 | msn.comKaleido Family Arts Festival crowdfunding after grant cuts leave it $50K shortAugust 26, 2023 | seekingalpha.comIDXG Interpace Biosciences, Inc.August 21, 2023 | tmcnet.comeSIM/iSIM Shipments to Exceed 1.4 Billion in 2028, Propelled by Ecosystem Simplification: Kaleido IntelligenceAugust 6, 2023 | finance.yahoo.comKLDO - Kaleido Biosciences, Inc.June 20, 2023 | technews.tmcnet.comIoT Wholesale Roaming Revenue to Exceed $8 Billion in 2028: Kaleido IntelligenceJune 3, 2023 | benzinga.comKaleido Creative Studio Launches OnNiche™: A Niche-Based Marketing System for Financial AdvisorsApril 26, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028April 26, 2023 | tmcnet.comKaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028March 28, 2023 | marketwatch.comConsumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido IntelligenceFebruary 22, 2023 | yahoo.comDirect-To-Satellite Communications to Generate $9 Billion in Airtime Revenues for Operators in 2030: Kaleido IntelligenceSee More Headlines Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2021Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KLDO CUSIPN/A CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$6.39 million OptionableNot Optionable Beta-0.06 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Kimberly HocknellSenior Vice President of Technical OperationsDr. Mark A. Wingertzahn Ph.D. (Age 53)Senior VP of R&D and Head of Development Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors KLDO Stock Analysis - Frequently Asked Questions How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.25 million. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK). When did Kaleido Biosciences IPO? Kaleido Biosciences (KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KLDO) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.